Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects
Phase 1
Completed
NCT02144714
| Condition | Healthy |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Completed |
|---|
| Enrollment | 189 participants |
|---|
| Interventions | SB5, EU sourced Humira®, US sourced Humira® |
|---|
| Start date | May, 2014 |
|---|
| Completion date | Sep, 2014 |
|---|
| Results posted | Sep 21, 2018 |
|---|
Summary
The purpose of this study is to compare the pharmacokinetics, safety, tolerability, and immunogenicity of SB5 and Humira (EU sourced Humira® and US sourced Humira®) in healthy subjects.
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
0 to 1680 hours post-dose · μg·h/mL
| SB5 (Proposed Adalimumab Biosimilar) | 2405.6 ± 825.93 μg·h/mL |
|---|
| EU Sourced Humira® | 2435.5 ± 915.66 μg·h/mL |
|---|
| US Sourced Humira® | 2422.6 ± 957.00 μg·h/mL |
|---|
Maximum Serum Concentration (Cmax)
pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose · μg/mL
| SB5 (Proposed Adalimumab Biosimilar) | 3.365 ± 0.9796 μg/mL |
|---|
| EU Sourced Humira® | 3.548 ± 1.1811 μg/mL |
|---|
| US Sourced Humira® | 3.488 ± 1.0779 μg/mL |
|---|
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
0 to 1680 hours post-dose · μg·h/mL
| SB5 (Proposed Adalimumab Biosimilar) | 2125.7 ± 689.92 μg·h/mL |
|---|
| EU Sourced Humira® | 2096.0 ± 791.28 μg·h/mL |
|---|
| US Sourced Humira® | 2101.9 ± 795.56 μg·h/mL |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.